Acute cardiac care & resuscitation
Association between vasopressin administration and mortality in patients with cardiogenic shock
Authors' conclusion
Vasopressin use in the first 24 hours was associated with lower adjusted mortality in patients with CS, particularly amongst those requiring HDV. The use of vasopressin in CS merits dedicated prospective evaluation.
Study context
- Population
- Adult patients admitted with a diagnosis of cardiogenic shock (CS) requiring vasopressors
- Participants
- 721 CS patients
- Comparison
- Vasopressin use in the first 24 hours and in-hospital mortality
- Vasopressinn = 207
- Outcome
- In-hospital mortality
Methodological detailsconsecutive adult patients
- Consecutive adult patients
Main finding
As reported in the abstract
High-dose vasopressors (HDV)
56.8%
- In-hospital mortality, all CS patients
- 38.1%
- In-hospital mortality without HDV (higher in the HDV group, 56.8% vs 29.2%)
- 29.2%
Further findings
In-hospital mortality, vasopressin
| Adjusted OR (95% CI) | P value | ||
|---|---|---|---|
| VasopressinPropensity adjusted; lower mortality with vasopressin | 0.59 (0.35–0.99) | P = 0.05 | |
| 0.20.5125Adjusted odds ratio (log scale) |
Mortality in the HDV group, vasopressin
| Unadjusted OR (95% CI) | P value | ||
|---|---|---|---|
| VasopressinHDV group; lower mortality with vasopressin | 0.54 (0.32–0.92) | P = 0.02 | |
| 0.20.5125Unadjusted odds ratio (log scale) |
Use of HDV and vasopressin · first 24 hours
- HDV
- 32.5%
- Vasopressin administered within the first 24 hours
- 207 (29%)
Original publication
Association between vasopressin administration and mortality in patients with cardiogenic shock. Am Heart J. Published 20 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →